Screener
SAB Biotherapeutics
SABSSAB Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of multi-specific, high-potency human immunoglobulin G (hIgG) therapies.
$308.44M+1,048%
Earnings
Next report
Nov 13, 2026 (in 2 months)Revenue estimate$125.0K
EPS estimate-$0.27
Competitors
By market cap
Profile
SAB Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of multi-specific, high-potency human immunoglobulin G (hIgG) therapies. The company utilizes a proprietary genetic engineering platform to produce human antibodies in large quantities without the need for human donors, focusing on disease-modifying treatments for immune and autoimmune disorders.
Competitive position
SAB Biotherapeutics maintains a unique competitive moat through its Tc-Bovine platform, which lacks a defined biosimilar pathway and eliminates reliance on human plasma donors.
GeographiesUnited States
Customer segmentsPatients, Healthcare providers
Business modelR&D intensive, IP licensing, Drug development
SuppliersGenetic engineering tools, Specialized livestock management, Laboratory equipment suppliers
CustomersClinical trial participants, Specialty pharmacies, Hospitals
CountryUnited States of America
Listed2021
Employees57.0
CEOSamuel J. Reich
SectorHealthcare
IndustryBiotechnology
Websitesab.bio
FilingsSEC EDGAR
FAQ
- What is SAB Biotherapeutics's market cap?
- SAB Biotherapeutics (SABS) has a market capitalization of $308.4M and trades on NASDAQ.
- Who are SAB Biotherapeutics's competitors?
- SAB Biotherapeutics's key competitors include Shattuck Labs, Inc. Common Stock, Q32 Bio Inc. Common Stock, Avalo Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is SAB Biotherapeutics headquartered?
- SAB Biotherapeutics is headquartered in United States of America and employs approximately 57 people. It has been publicly traded since 2021.